{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T09:23:19Z","timestamp":1775208199401,"version":"3.50.1"},"reference-count":27,"publisher":"Sociedade Brasileira de Cardiologia","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.36660\/abc.20200353","type":"journal-article","created":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T19:07:51Z","timestamp":1632251271000},"page":"531-541","source":"Crossref","is-referenced-by-count":5,"title":["Preditores de Mortalidade Total e Eventos Arr\u00edtmicos Graves em Pacientes com Insufici\u00eancia Card\u00edaca N\u00e3o Isqu\u00eamica: O Papel da Galectina-3"],"prefix":"10.36660","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7839-2054","authenticated-orcid":false,"given":"Adriano Nunes","family":"Kochi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1489-5349","authenticated-orcid":false,"given":"Mauricio","family":"Pimentel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Andrades","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiago","family":"Zimerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9980-9114","authenticated-orcid":false,"given":"Leandro Ioschpe","family":"Zimerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6557-393X","authenticated-orcid":false,"given":"Luis Eduardo","family":"Rohde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22636","published-online":{"date-parts":[[2021,9,1]]},"reference":[{"issue":"6","key":"key20210921150738_B1","first-page":"433","article-title":"I Brazilian Registry of Heart Failure - Clinical Aspects, Care Quality and Hospitalization Outcomes","volume":"104","author":"Albuquerque","year":"2015","unstructured":"1. Albuquerque DC, Souza Neto JD, Bacal F, Rohde LE, Bernardez-Pereira S, Berwanger O, et al. I Brazilian Registry of Heart Failure - Clinical Aspects, Care Quality and Hospitalization Outcomes. Arq Bras Cardiol. 2015;104(6):433-42.","journal-title":"Arq Bras Cardiol"},{"issue":"9169","key":"key20210921150738_B2","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)","volume":"353","author":"MERIT Investigators","year":"1999","unstructured":"2. MERIT Investigators. Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001-7.","journal-title":"Lancet"},{"issue":"2","key":"key20210921150738_B3","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ijcard.2012.07.014","article-title":"Sudden cardiac death in non-ischemic dilated cardiomyopathy: A critical appraisal of existing and potential risk stratification tools","volume":"167","author":"Koutalas","year":"2013","unstructured":"3. Koutalas E, Kanoupakis E, Vardas P. Sudden cardiac death in non-ischemic dilated cardiomyopathy: A critical appraisal of existing and potential risk stratification tools. Int J Cardiol. 2013;167(2):335-41.","journal-title":"Int J Cardiol"},{"issue":"26","key":"key20210921150738_B4","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJM199612263352601","article-title":"Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia","volume":"335","author":"Moss","year":"1996","unstructured":"4. Moss AJ, Hall WJ, Cannon DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med. 1996;335(26):1933-40.","journal-title":"N Engl J Med"},{"issue":"12","key":"key20210921150738_B5","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa013474","article-title":"Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction","volume":"346","author":"Moss","year":"2002","unstructured":"5. Moss AJ, Zareba W, Hall J, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877-83.","journal-title":"N Engl J Med"},{"key":"key20210921150738_B6","first-page":"225","article-title":"Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure","volume":"352","author":"Bardy","year":"2005","unstructured":"6. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. The Sudden Cardiac Death in Heart Failure (SCD-HeFT) Trial. N Engl J Med. 2005 Jan 20;352:225-37.","journal-title":"The Sudden Cardiac Death in Heart Failure (SCD-HeFT) Trial. N Engl J Med"},{"issue":"21","key":"key20210921150738_B7","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMoa033088","article-title":"Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy","volume":"350","author":"Kadish","year":"2004","unstructured":"7. Kadish A, Dyer A, Daubert JP, Quigg R, Estes M, Anderson KP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350(21):2151-8.","journal-title":"N Engl J Med"},{"issue":"13","key":"key20210921150738_B8","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMoa1608029","article-title":"Defibrillator implantation in patients with nonischemic systolic heart failure","volume":"375","author":"K\u00f8ber","year":"2016","unstructured":"8. K\u00f8ber L, Thune JJ, Nielsen JC, Haarbo J, Videb\u00e6k L, Korup E, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016;375(13):1221-30.","journal-title":"N Engl J Med"},{"issue":"9","key":"key20210921150738_B9","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/jama.2013.1363","article-title":"Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy","volume":"309","author":"Gulati","year":"2013","unstructured":"9. Gulati A, Jabbour A, Ismail TF, Guha K, Khwara J, Raza S, et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA. 2013;309(9):896-908.","journal-title":"JAMA"},{"key":"key20210921150738_B10","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1007\/s10554-016-0958-1","article-title":"Cardiac magnetic resonance and galectin-3 level as predictors of prognostic outcomes for non-ischemic cardiomyopathy patients","volume":"32","author":"Hu","year":"2016","unstructured":"10. Hu DJ, Xu J, Du W, Zhang JX, Zhong M, Zhou YN. Cardiac magnetic resonance and galectin-3 level as predictors of prognostic outcomes for non-ischemic cardiomyopathy patients. Int J Cardiovasc Imaging. 2016;32:1725-33.","journal-title":"Int J Cardiovasc Imaging"},{"issue":"10","key":"key20210921150738_B11","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.jacc.2017.07.712","article-title":"Outcomes of cardiac resynchronization therapy with or without defibrillation in patients with nonischemic cardiomyopathy","volume":"70","author":"Leyva","year":"2017","unstructured":"11. Leyva F, Zegard A, Acquaye E, Gubran C, Taylor R, Foley PWX, et al. Outcomes of cardiac resynchronization therapy with or without defibrillation in patients with nonischemic cardiomyopathy. J Am Coll Cardiol. 2017;70(10):1216-27.","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"key20210921150738_B12","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1161\/CIRCULATIONAHA.105.549659","article-title":"Magnetic resonance assessment of the substrate for inducible ventricular tachycardia in nonischemic cardiomyopathy","volume":"112","author":"Nazarian","year":"2005","unstructured":"12. Nazarian S, Bluemke DA, Lardo AC, Zviman MM, Watkins SP, Dickfeld TL, et al. Magnetic resonance assessment of the substrate for inducible ventricular tachycardia in nonischemic cardiomyopathy. Circulation. 2005;112(18):2821-5.","journal-title":"Circulation"},{"issue":"24","key":"key20210921150738_B13","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1136\/hrt.2009.183335","article-title":"Non-invasive evaluation of myocardial fibrosis: implication for the clinician","volume":"96","author":"Leong","year":"2010","unstructured":"13. Leong DP, Madsen PL, Selvanayagam JB. Non-invasive evaluation of myocardial fibrosis: implication for the clinician. Heart. 2010;96(24):2016-24.","journal-title":"Heart"},{"issue":"1","key":"key20210921150738_B14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11897-010-0004-x","article-title":"Galectin-3 in cardiac remodeling and heart failure","volume":"7","author":"Boer","year":"2010","unstructured":"14. Boer RA, Yu L, Veldhuisen DJ. Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep. 2010;7(1):1-8.","journal-title":"Curr Heart Fail Rep"},{"issue":"12","key":"key20210921150738_B15","article-title":"Prognostic value of serial galectin-3 measurements in patients with acute heart failure","volume":"6","author":"Vark","year":"2017","unstructured":"15. Vark LC, Lesman-Leegte I, Baart SJ, Postmus D, Pinto YM, Boer RA, et al. Prognostic value of serial galectin-3 measurements in patients with acute heart failure. J Am Heart Assoc. 2017;6(12):e003700.","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"key20210921150738_B16","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/jce.12364","article-title":"Osteopontin and galectin-3 predict the risk of ventricular tachycardia and fibrillation in heart failure patients with implantable defibrillators","volume":"25","author":"Francia","year":"2014","unstructured":"16. Francia P, Adduci C, Semprini L, Borro M, Ricotta A, Sensini I, et al. Osteopontin and galectin-3 predict the risk of ventricular tachycardia and fibrillation in heart failure patients with implantable defibrillators. J Cardiovasc Electrophysiol. 2014;25(6):609-16.","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"2","key":"key20210921150738_B17","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s10840-016-0213-7","article-title":"Predictors of serious arrhythmic events in patients with nonischemic heart failure","volume":"48","author":"Pimentel","year":"2017","unstructured":"17. Pimentel M, Zimerman A, Chemello D, Giaretta V, Andrades M, Silvello D, et al. Predictors of serious arrhythmic events in patients with nonischemic heart failure. J Interv Card Electrophysiol. 2017;48(2):131-9.","journal-title":"J Interv Card Electrophysiol"},{"key":"key20210921150738_B18","doi-asserted-by":"crossref","DOI":"10.1002\/9780470316696","volume-title":"Multiple imputation for nonresponse in surveys","author":"Rubin","year":"1987","unstructured":"18. Rubin DB. Multiple imputation for nonresponse in surveys. New York: John Wiley & Sons; 1987."},{"issue":"4","key":"key20210921150738_B19","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.bbagen.2005.12.020","article-title":"Galectin-3: an open-ended story","volume":"1760","author":"Dumic","year":"2006","unstructured":"19. Dumic J, Dabelic S, Fl\u00f6gel M. Galectin-3: an open-ended story. Biochim Biophys Acta. 2006;1760(4):616-35.","journal-title":"Biochim Biophys Acta"},{"issue":"13","key":"key20210921150738_B20","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1073\/pnas.0511167103","article-title":"Galectin-3 regulates myofibroblast activation and hepatic fibrosis","volume":"103","author":"Henderson","year":"2006","unstructured":"20. Henderson NC, Mackinnon AC, Farnworth SL, Poirier F, Russo FP, Iredale JP, et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA. 2006;103(13):5060-5.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"key20210921150738_B21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1161\/ATVBAHA.112.300569","article-title":"Galectin-3 mediates aldosterone-induced vascular fibrosis","volume":"33","author":"Calvier","year":"2013","unstructured":"21. Calvier L, Miana M, Reboul P, Cachofeiro V, Martinez-Martinez E, Boer RA, et al. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol. 2013;33(1):67-75.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"key20210921150738_B22","doi-asserted-by":"crossref","first-page":"577","DOI":"10.5603\/CJ.2013.0157","article-title":"The association between galectin-3 and clinical parameters in patients with first acute myocardial infarction treated with primary percutaneous coronary angioplasty","volume":"20","author":"Szadkowska","year":"2013","unstructured":"22. Szadkowska I, Wlaze\u0142 RN, Miga\u0142a M, Szadkowski K, Zieli\u0144ska M, Paradowski M, et al. The association between galectin-3 and clinical parameters in patients with first acute myocardial infarction treated with primary percutaneous coronary angioplasty. Cardiol J. 2013;20(6):577-82.","journal-title":"Cardiol J"},{"issue":"6","key":"key20210921150738_B23","doi-asserted-by":"crossref","first-page":"197","DOI":"10.25011\/cim.v39i6.27528","article-title":"Galectin-3: a biochemical marker to detect paroxysmal atrial fibrillation?","volume":"39","author":"Selcoki","year":"2016","unstructured":"23. Selcoki Y, Aydin HI, Celik TH, Isleyen A, Erayman A, Demircelik MB, et al. Galectin-3: a biochemical marker to detect paroxysmal atrial fibrillation? Clin Investig Med. 2016;39(6):197-203.","journal-title":"Clin Investig Med"},{"issue":"5","key":"key20210921150738_B24","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.amjcard.2014.12.021","article-title":"Effects of persistent atrial fibrillation on serum galectin-3 levels","volume":"115","author":"Gurses","year":"2017","unstructured":"24. Gurses KM, Yalcin MU, Kocyigit D, Canpinar H, Banu E, Yorgun H, et al. Effects of persistent atrial fibrillation on serum galectin-3 levels. Am J Cardiol. 2017;115(5):647-51.","journal-title":"Am J Cardiol"},{"issue":"10","key":"key20210921150738_B25","doi-asserted-by":"crossref","first-page":"997","DOI":"10.5603\/KP.a2017.0118","article-title":"The usefulness of soluble ST2 and galectin-3 as novel biomarkers for better risk stratification in hypertrophic cardiomyopathy","volume":"75","author":"Gawor","year":"2017","unstructured":"25. Gawor M, \u015apiewak M, Janas J, Ko\u017cuch K, Wr\u00f3bel A, Mazurkiewicz L, et al. The usefulness of soluble ST2 and galectin-3 as novel biomarkers for better risk stratification in hypertrophic cardiomyopathy. Kardiol Pol. 2017;75(10):997-1004.","journal-title":"Kardiol Pol"},{"issue":"1","key":"key20210921150738_B26","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2017-000750","article-title":"The prognostic value of sST2 and galectin-3 considering different aetiologies in non-ischaemic heart failure","volume":"5","author":"Binas","year":"2018","unstructured":"26. Binas D, Daniel H, Richter A, Ruppert V, Schl\u00fcter KD, Schieffer V, et al. The prognostic value of sST2 and galectin-3 considering different aetiologies in non-ischaemic heart failure. Open Heart. 2018;5(1):e000750.","journal-title":"Open Heart"},{"key":"key20210921150738_B27","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ijcard.2014.12.137","article-title":"Prognostic value of serum galectin-3 in patients with heart failure: a meta-analysis","volume":"182","author":"Chen","year":"2015","unstructured":"27. Chen A, Hou W, Zhang Y, Chen Y, He B. Prognostic value of serum galectin-3 in patients with heart failure: a meta-analysis. Int J Cardiol. 2015 Mar 1;182:168-70.","journal-title":"Int J Cardiol"}],"container-title":["Arquivos Brasileiros de Cardiologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/abccardiol.org\/article\/preditores-de-mortalidade-total-e-eventos-arritmicos-graves-em-pacientes-com-insuficiencia-cardiaca-nao-isquemica-o-papel-da-galectina-3\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T13:06:22Z","timestamp":1747400782000},"score":1,"resource":{"primary":{"URL":"https:\/\/abccardiol.org\/article\/preditores-de-mortalidade-total-e-eventos-arritmicos-graves-em-pacientes-com-insuficiencia-cardiaca-nao-isquemica-o-papel-da-galectina-3\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,9,1]]},"published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.36660\/abc.20200353"],"URL":"https:\/\/doi.org\/10.36660\/abc.20200353","relation":{},"ISSN":["0066-782X","1678-4170"],"issn-type":[{"value":"0066-782X","type":"print"},{"value":"1678-4170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9]]}}}